Bionest

Are the Blues Ending for Bluebird?

Gene therapy developer bluebird bio may be turning a corner, with recent FDA approvals for two of its rare disease therapeutics.

Bionest

ASH 2021 Update: Part 2

A look at new hematology therapy developments for hemophilia, beta thalassemia and sickle cell disease presented at ASH 2021.

Bionest

ASH 2021 Update: Part One

Are anti-CD38 antibodies & CAR-T treatments living up to their promise for multiple myeloma patients? We examine clinical trial results shared at ASH2021

Bionest

What’s Next for mRNA?

Beyond COVID and cancer: In which indications will we see mRNA technology succeed next? And what technological advances might next-generation mRNA platforms offer over those used in the COVID-19 vaccines?

Bionest

New Strategies Against a Hard-to-Treat Killer — Pancreatic Cancer

Pancreatic cancer was the third leading cause of cancer-related death in the United States in 2018. This year, experts estimate that 56,770 new cases will be diagnosed and 45,750 deaths will be recorded. Pancreatic cancer is especially lethal because in its early stages, when the disease is easiest to treat, patients are usually asymptomatic. The disease...